A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Conditions: Prostate Cancer

Interventions: Drug: Tinengotinib; Drug: abiraterone acetate; Drug: Prednisone or Enzalutamide; Drug: Tinengotinib

Sponsors: Memorial Sloan Kettering Cancer Center; TransThera Sciences

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 14, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments